The Use of 17 Alpha-Hydroxyprogesterone Caproate (17P) in Women with Cervical Cerclage

ABSTRACT

Our objective was to compare the incidence of recurrent spontaneous preterm delivery (SPTD) in patients with cervical cerclage treated with weekly 17 α-hydroxyprogesterone caproate (17P) injections versus daily outpatient nursing surveillance (ONS) without 17P. Included in this retrospective cohort study were singleton gestations with cerclage placed at the discretion of the provider due to prior SPTD, delivering between January 1, 2004 and May 1, 2006. The study group (n = 232) consisted of women receiving once-weekly nursing visit and 17P injection. The control group (n = 1650) consisted of women enrolled for ONS (twice-daily electronic uterine contraction monitoring and nursing assessment). Data were further stratified by the number of prior preterm deliveries (1, > 1). Primary study outcome was the incidence of SPTD. No difference in rates of recurrent SPTD at < 37 or < 35 weeks were observed between the study and control groups. Study patients were less likely to be diagnosed with preterm labor (PTL) than controls (45.7% versus 70.8%, respectively; p < 0.001). The incidence of preterm premature rupture of membranes was similar between the groups (8.6% versus 8.1%; p = 0.770). We concluded that the incidence of recurrent SPTD was similar in women with cerclage treated with 17P or ONS, although women receiving 17P had a lower incidence of PTL. This benefit of 17P should be considered when managing patients with prior SPTD and cerclage.

KEYWORDS

Recurrent spontaneous preterm delivery - cervical cerclage - 17 α-hydroxyprogesterone caproate

REFERENCES

• 1 Martin J A, Hamilton B E, Sutton P D et al.. Births: Final Data for 2004. National Vital Statistics Reports. Hyattsville, MD; National Center for Health Statistics 2006
• 2 Iams J D. Abnormal cervical competence. In: Creasy RK and Resnick R Maternal Fetal Medicine Principles and Practice. 5th ed. Philadelphia; WB Saunders 2004: 603-622
• 3 American College of Obstetricians and Gynecologists . ACOG Practice Bulletin. Cervical insufficiency.  Obstet Gynecol. 2003;  102 1091-1099
• 4 Berghella V, Odibo A O, To M S, Rust O A, Althuisius S M. Cerclage for short cervix on ultrasonography: meta-analysis of trials using individual patient-level data.  Obstet Gynecol. 2005;  106 181-189
• 5 Meis P J, Klebanoff M, Thom E et al.. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.  N Engl J Med. 2003;  348 2379-2385
• 6 American College of Obstetricians and Gynecologists . ACOG Committee Opinion. Use of progesterone to reduce preterm birth.  Obstet Gynecol. 2003;  102 1115-1116
• 7 Gonzalez-Quintero V H, Istwan N B, Rhea D J, Smarkusky L, Hoffman M C, Stanziano G J. Gestational age at initiation of 17a-hydroxyprogesterone caproate (17P) and recurrent preterm delivery.  J Matern Fetal Neonatal Med. 2007;  20 249-252
• 8 How H Y, Barton J R, Istwan N B, Rhea D J, Stanziano G J. Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter?.  Am J Obstet Gynecol. 2007;  197 260 , e1-e4
• 9 Facchinetti F, Paganelli S, Comitini G, Dante G, Volpe A.. Cervical length changes during preterm cervical ripening: effects of 17-α-hydroxyprogesterone caproate.  Am J Obstet Gynecol. 2007;  196(5) 453 , e1-e4